Rhythm Pharmaceuticals (RYTM) Shares Outstanding (Weighted Average) (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Shares Outstanding (Weighted Average) data on file, last reported at $68.0 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $68.0 million, up 7.79% year-over-year; the trailing twelve-month figure through Mar 2026 was $68.0 million (up 7.79% YoY), and the FY2025 annual result was $65.0 million, up 6.54% from the prior year.
• Shares Outstanding (Weighted Average) improved to $68.0 million in Q1 2026 per RYTM's latest filing, from $65.0 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $68.0 million in Q1 2026 and troughed at $50.3 million in Q1 2022.
• A 5-year average of $58.7 million and a median of $60.1 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2022 and 2023: Shares Outstanding (Weighted Average) rose 2.71% in 2022, then climbed 12.76% in 2023.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $52.1 million in 2022, then grew by 10.65% to $57.7 million in 2023, then climbed by 5.76% to $61.0 million in 2024, then rose by 6.54% to $65.0 million in 2025, then rose by 4.6% to $68.0 million in 2026.
• Business Quant data shows RYTM's Shares Outstanding (Weighted Average) at $68.0 million in Q1 2026, $65.0 million in Q4 2025, and $64.3 million in Q3 2025.